Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1007 | Complete thrombophilic profile testing by multiplex PCR Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D020767 | Intracranial Thrombosis NIH | 1.00 |
| D019851 | Thrombophilia NIH | 0.50 |
| D020246 | Venous Thrombosis NIH | 0.29 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0100724 | Hypercoagulability HPO | 0.50 |
| HP:0002625 | Deep venous thrombosis HPO | 0.29 |
Navigate: Correlations HPO
There is one clinical trial.
A novel zoonotic coronavirus was discovered in Wuhan (Hubei Province, China) mid-December 2019 and was named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The virus rapidly spread to the rest of the world, including Europe and explicitly affects the respiratory system, generating Coronavirus disease 2019 (COVID-19). This study is a monocentric interventional prospective cohort study. After signing a written informed consent, participants will be recruited for questionnaire completion and blood sampling. Sample storage and analysis will be performed at the laboratory of microbiology of the UZ Brussel. - To document SARS-CoV-2 seroprevalence among employees of the UZ Brussel at day 0 (i.e. at beginning of the study, planned early May 2020), month 2 and month 5. - To document number of SARS-CoV-2 seroconversions among employees of the UZ Brussel over a period of 5 months.
Description: - To document SARS-CoV-2 seroprevalence among employees of the UZ Brussel at day 0 (i.e. at beginning of the study, planned early May 2020), month 2 and month 5.
Measure: Seroprevalence Time: Change from baseline to 2 months and 5 months timepointDescription: - To document number of SARS-CoV-2 seroconversions among employees of the UZ Brussel over a period of 5 months.
Measure: seroconversions Time: Change from baseline to 2 months and 5 months timepointDescription: - To document the incidence of new definite cases of COVID-19 (based on self-reported positive PCR testing on nasopharyngeal swab) among employees of the UZ Brussel over a period of five months.
Measure: Incidence of definite cases Time: Change from baseline to 2 months and 5 months timepointDescription: - To document the incidence of new probable cases of COVID-19 (based on study questionnaire) among employees of the UZ Brussel over a period of five months.
Measure: Incidence of probable cases Time: Change from baseline to 2 months and 5 months timepointDescription: - To document the SARS-CoV-2 antibody kinetics after confirmed and probable COVID-19. Specifically (1) electrostatic interactions, (2) dispersion forces, (3) hydrogen bonds, and (4) hydrophobic interactions.
Measure: Antibody kinetics Time: Change from baseline to 2 months and 5 months timepointDescription: - To investigate potential work-related risk factors for SARS-CoV-2 infection among employees of the UZ Brussel.
Measure: Potential work-related risk factors Time: Change from baseline to 2 months and 5 months timepointDescription: - To quantify the proportion of asymptomatic seroconversions among employees of the UZ Brussel over a period of five months.
Measure: Proportion of asymptomatic seroconversions Time: Change from baseline to 2 months and 5 months timepointDescription: - To document the concerns of HCW and non-HCW about their safety for infection with COVID-19.
Measure: Concerns for safety for infection with COVID-19 Time: Change from baseline to 2 months and 5 months timepointAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports